By Cristina Roca 
 

Novartis AG said late Friday that the U.S. Food & Drug Administration has approved Scemblix for two indications in chronic myeloid leukemia.

The Swiss pharmaceutical company said the treatment received accelerated approval for one indication and full approval for a second indication. This means continued approval for the first indication may be contingent on confirmatory evidence.

 

Write to Cristina Roca at cristina.roca@wsj.com

 

(END) Dow Jones Newswires

November 01, 2021 02:20 ET (06:20 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Grafico Azioni Novartis (NYSE:NVS)
Storico
Da Feb 2024 a Mar 2024 Clicca qui per i Grafici di Novartis
Grafico Azioni Novartis (NYSE:NVS)
Storico
Da Mar 2023 a Mar 2024 Clicca qui per i Grafici di Novartis